BrainsWay Ltd.

Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.

zacks.com - 2026-07-20 15:15:53

BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care

globenewswire.com - 2026-07-20 07:30:00

Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care

globenewswire.com - 2026-07-16 07:30:00

BWAY, HTLD and NCNO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 14th, 2026.

zacks.com - 2026-07-14 11:01:20

HTLD, MEOH, NCNO, JD and BWAY have been added to the Zacks Rank #1 (Strong Buy) List on July 14th, 2026.

zacks.com - 2026-07-14 08:46:08

Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD), making comorbid depression one of the most common and clinically significant complications of PTSD

globenewswire.com - 2026-06-29 07:30:00

BURLINGTON, Mass. and JERUSALEM, June 22, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing favorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol. The announcement comes after a series of favorable policy changes, the latest of which is a recently issued policy covering 2 million members in South Carolina allowing for coverage of SWIFT, in addition to various other increases in Deep TMS coverage for both major depressive disorder (MDD) and obsessive-compulsive disorder (OCD) patients.

globenewswire.com - 2026-06-22 07:30:00

Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatment, with Decline in Severe Functional Impairment from 85% to 0% Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatment, with Decline in Severe Functional Impairment from 85% to 0%

globenewswire.com - 2026-06-09 07:30:00

Investment in provider servicing clinics in Illinois is latest in series of similar transactions by BrainsWay with leading North American mental health providers to raise awareness and expand access to transformative care Investment in provider servicing clinics in Illinois is latest in series of similar transactions by BrainsWay with leading North American mental health providers to raise awareness and expand access to transformative care

globenewswire.com - 2026-05-18 07:30:00

BrainsWay Ltd. (BWAY) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-13 11:20:48

Brainsway NASDAQ: BWAY reported a strong start to 2026, with first-quarter revenue rising 35% year over year as the company expanded placements of its Deep TMS systems and continued to build its recurring revenue base.

marketbeat.com - 2026-05-13 10:08:23

R evenue grew approximately   35 % y ear- o ver- y ear to   $1 5 .5 million  for Q1 2026

globenewswire.com - 2026-05-13 07:30:00

Here is how Brainsway Ltd. Sponsored ADR (BWAY) and CG Oncology, Inc. (CGON) have performed compared to their sector so far this year.

zacks.com - 2026-05-04 10:40:42

Brainsway (BWAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

zacks.com - 2026-04-29 09:56:26

BURLINGTON, Mass. and JERUSALEM, April 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation technologies, today announced that it will report its first quarter 2026 financial results and recent operational highlights before the open of the U.S. financial markets on Wednesday, May 13, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

globenewswire.com - 2026-04-29 08:00:00

The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.

zacks.com - 2026-04-27 09:31:07

BrainsWay continues to deliver strong growth and margin improvement, supported by investments in TMS service providers and recurring revenue expansion. BWAY's accelerated protocol and expanded indications, including adolescent depression, are supportive of further growth. TMS is a relatively expensive treatment option though with a high patient burden, making the impeding entry of psychedelics (psilocybin, LSD, DMT) into the market a serious threat.

seekingalpha.com - 2026-04-24 10:29:19

On April 22, 2026, BrainsWay Ltd (BWAY) shares rose 3.4% today, bringing the current price to $15.85. The stock has seen significant upward movement in the past

gurufocus.com - 2026-04-22 18:10:00